Talaris Therapeutics Financials
TALSDelisted Stock | USD 2.98 0.10 3.25% |
Talaris |
Please note, the imprecision that can be found in Talaris Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Talaris Therapeutics. Check Talaris Therapeutics' Beneish M Score to see the likelihood of Talaris Therapeutics' management manipulating its earnings.
Talaris Therapeutics Stock Summary
Talaris Therapeutics competes with Edgewise Therapeutics, Adicet Bio, Cullinan Oncology, Vor Biopharma, and CytomX Therapeutics. Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky. Talaris Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 128 people.Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US87410C1045 |
Business Address | 570 South Preston |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | talaristx.com |
Phone | 502 398 9250 |
Currency | USD - US Dollar |
Talaris Therapeutics Key Financial Ratios
Talaris Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Talaris Therapeutics's current stock value. Our valuation model uses many indicators to compare Talaris Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Talaris Therapeutics competition to find correlations between indicators driving Talaris Therapeutics's intrinsic value. More Info.Talaris Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Talaris Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Talaris Therapeutics Market Pulse
Quote | 2.98 |
Change(%) | 3.25 |
Change | 0.10 |
Open | 3.08 |
Low | 2.98 |
High | 3.08 |
Volume | 0 |
Exchange | NASDAQ |
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Talaris Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Talaris has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Talaris Therapeutics' financials are consistent with your investment objective using the following steps:- Review Talaris Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Talaris Therapeutics' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Talaris Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Talaris Therapeutics' stock is overvalued or undervalued.
Talaris Therapeutics December 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Talaris Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Talaris Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Talaris Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Talaris Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Talaris Therapeutics's daily price indicators and compare them against related drivers.
Downside Deviation | 3.47 | |||
Information Ratio | 0.1114 | |||
Maximum Drawdown | 27.39 | |||
Value At Risk | (5.95) | |||
Potential Upside | 7.32 |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Talaris Stock
If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |